Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
-
COVID-19 | FDA | HIV | Infectious Disease | Vaccine
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had concluded exploratory talks with the European Commission…
-
iBio advanced COVID-19 LicKM-subunit vaccine candidate, IBIO-201
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate…
-
U.S. COVID-19 cases may be substantially underestimated
On Sept. 9, 2020, UC Berkeley School of Public Health researchers reported that probability analysis showed the U.S….
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Medicine | Non-Profit Research | Stem Cell | Therapeutics
California’s Stem Cell Agency and the Chan Zuckerberg Initiative partnered to create COVID-19 database
On Sept. 8, 2020, a new collaboration between the California Institute for Regenerative Medicine (CIRM) and the Chan…
-
Vaxart’s oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal…
-
DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II Assay
On Sept. 7, 2020, DiaSorin Molecular announced that it had received U.S. Food and Drug Administration (FDA) Clearance…
-
Persistent immune memory of COVID-19 found in recovered patient T cells
On Sept. 4, 2020, the University of Oxford researchers found that natural infection with COVID-19 produces a robust…
-
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, data from Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in…
-
ADMA Biologics launched COVID-19 ImmunoRank Neutralization MICRO-ELISA for detection of SARS-CoV-2
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…
-
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
-
OraSure’s ORAcollect-RNA device Included in EUA granted to MiraDx for SARS-CoV-2 test
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ﾷRNA (OR-100) collection device was included along with other…
-
Virginia Tech researchers began testing campus wastewater for COVID-19
On Sept. 3, 2020, a team of Virginia Tech researchers announced that they will begin testing wastewater at…
-
Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…
-
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
-
OPKO Health’s BioReference Laboratories announced New York City Schools COVID-19 testing program
On Sept. 2, 2020, BioReference Laboratories, an OPKO Health company, began testing New York City principals, teachers and…
-
Aegis Sciences awarded $66 million NIH grant to rapidly expand COVID-19 test capacity
On Sept. 2, 2020, Aegis Sciences announced that it had been selected to participate in the National Institutes…
-
PathGroup selected by NIH to become RADx program ‘mega-lab’ for COVID-19 testing
On Sept. 2, 2020, PathGroup announced the award of a funding grant from the National Institutes of Health…
-
NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…
-
Custom face shields aimed to block droplets, tackled COVID-19 for football players
On Sept. 2, 2020, researchers from the Virginia Tech Helmet Lab announced the development of a football helmet…
-
NIH to boost national COVID-19 testing capacity
On Sept. 2, 2020, the National Institutes of Health (NIH) announced $129.3 million in scale-up and manufacturing support…
-
Broad Institute provided COVID-19 screening for students, faculty and staff at more than 100 colleges and universities
On Sept. 2, 2020, Broad Institute of MIT and Harvard announced it had partnered with 108 public and…
-
Aegis Life launched to fight COVID-19 via DNA vaccines and therapeutics enabled by Fusogenix delivery technology
On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated…
-
NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
On Sept. 1, 2020, the National Institutes of Health announced that it had launched a study to track…
-
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
-
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
Lenzilumab COVID-19 case-control study published in Mayo Clinic Proceedings Journal
On Sept. 1, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80%…
-
Sanofi updated Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the US
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
-
HDT BIO received NIH contract to advance novel RNA/LION COVID-19 vaccine into clinical trials
On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and…
